Drug Trial Radar · NCT07372703
Study of the Safety, Tolerability, Pharmacokinetics of VV913 Capsules in Chinese Healthy Participants
Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Jan 29, 2026
Primary completion
Sep 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Jan 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics characteristics of VV913 Capsules in healthy adults.
Conditions
- Healthy Volunteers
Interventions
VV913 1mg groupDrug
6 participants will receive VV913 1mg orally; 2 participants will receive placebo orally.
VV913 2mg groupDrug
6 participants will receive VV913 2mg orally; 2 participants will receive placebo orally.
VV913 4mg groupDrug
6 participants will receive VV913 4mg orally; 2 participants will receive placebo orally.
VV913 8mg groupDrug
6 participants will receive VV913 8mg orally; 2 participants will receive placebo orally.
VV913 15mg groupDrug
6 participants will receive VV913 15mg orally; 2 participants will receive placebo orally.
VV913 25mg groupDrug
6 participants will receive VV913 25mg orally; 2 participants will receive placebo orally.
VV913 40mg groupDrug
6 participants will receive VV913 40mg orally; 2 participants will receive placebo orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: 72 hours after administration
- TmaxTime frame: 72 hours after administration
- t1/2Time frame: 72 hours after administration
- AUC0-tTime frame: 72 hours after administration
- AUC0-∞Time frame: 72 hours after administration
- KelTime frame: 72 hours after administration
- Vd/FTime frame: 72 hours after administration
- MRTTime frame: 72 hours after administration
- CL/FTime frame: 72 hours after administration
- AE & SAETime frame: from day1 to day7 after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.